Wednesday, June 7, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
-
Associate Professor
Medical College of Wisconsin
Brookfield, Wisconsin, United States
Professor
Head of Lymphoma Group
Lymphoma and Chronic Lymphoproliferative Syndromes Unit
Institute of Hematology "L. e A. Serà gnoli"
University of Bologna
Bologna, Italy
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™
This activity is intended for hematology/oncology specialists, pathologists, and oncology care teams.
The goal of this activity is for learners to be better able to assess the latest data related to the use of BTK inhibitor therapy in patients with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and MCL, and integrate their use and management into current and future clinical practice.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
-
Associate Professor
Medical College of Wisconsin
Brookfield, Wisconsin, United States
Professor
Head of Lymphoma Group
Lymphoma and Chronic Lymphoproliferative Syndromes Unit
Institute of Hematology "L. e A. Serà gnoli"
University of Bologna
Bologna, Italy
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Developed through a collaboration between The Leukemia & Lymphoma Society and Medscape Oncology.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME Released: 3/30/2023
Valid for credit through: 3/30/2024
processing....
